In a three-month study at one clinic in China, adults receiving tirzepatide lost more weight on average than those receiving semaglutide. The comparison included 183 adults with obesity and without diabetes. Physicians chose each person’s treatment, and researchers compared the groups retrospectively [1].
What the doses represent
The study used weekly semaglutide 1.7 mg (86 participants) and weekly tirzepatide 5 mg (97 participants) [1]. In the U.S. weight-management labels, 1.7 mg weekly is a Wegovy maintenance option, with 2.4 mg recommended and Wegovy HD available for some adults who need more weight reduction. The Zepbound label lists 5 mg, 10 mg and 15 mg as weight-management maintenance options [2] [3].
Our guide to doses reached in routine care explains why an available dose can differ from the one people take. This study’s results apply to the two regimens it compared over three months. It cannot establish a dose conversion between the medications.
Weight, appetite and side effects
Average weight loss was 11.02 kg with tirzepatide and 8.15 kg with semaglutide, an unadjusted difference of 2.87 kg (95% confidence interval 1.32–4.41 kg). The authors also estimated that the share reaching the study’s 10% weight-loss threshold was 21.50 percentage points higher with tirzepatide (95% confidence interval 7.45–35.55 points)[1].
The two questionnaires tracked control of eating and appetite. The authors did not report a clear difference between groups in cravings and appetite scores. They also did not detect statistically significant differences in gastrointestinal or psychiatric side effects over three months [1].
How dose affects a price comparison
The dose pricing tool helps compare whether quoted prices change across dose levels. Use the price for the dose you are comparing. This study reports weight and appetite outcomes and does not estimate what either regimen costs.